MRVL vs. BBIO
MRVL (Marvell Technology, Inc.) and BBIO (BridgeBio Pharma, Inc.) are both stocks. MRVL operates in Semiconductors (Technology), while BBIO operates in Biotechnology (Healthcare). Over the past 5 years, MRVL returned 40.49%/yr vs 0.88%/yr for BBIO. At a 0.28 correlation, their price movements are largely independent.
Performance
MRVL vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MRVL achieves a 229.54% return, which is significantly higher than BBIO's -12.67% return.
MRVL
- 1D
- -0.36%
- 1M
- 57.18%
- YTD
- 229.54%
- 6M
- 231.70%
- 1Y
- 302.72%
- 3Y*
- 64.86%
- 5Y*
- 40.49%
- 10Y*
- 40.68%
BBIO
- 1D
- -1.11%
- 1M
- -2.64%
- YTD
- -12.67%
- 6M
- -11.11%
- 1Y
- 68.47%
- 3Y*
- 58.58%
- 5Y*
- 0.88%
- 10Y*
- —
MRVL vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
MRVL Marvell Technology, Inc. | 229.54% | -22.82% | 83.79% | 63.68% | -57.48% | 84.62% | 80.25% | 12.84% |
BBIO BridgeBio Pharma, Inc. | -12.67% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 14.51% |
Correlation
The correlation between MRVL and BBIO is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Jun 27, 2019 | 0.28 |
Fundamentals
MRVL:
$249.86B
BBIO:
$13.01B
MRVL:
$2.90
BBIO:
-$3.76
MRVL:
27.99
BBIO:
22.81
MRVL:
$8.72B
BBIO:
$566.04M
MRVL:
$4.41B
BBIO:
$538.20M
MRVL:
$4.27B
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MRVL vs. BBIO — Risk / Return Rank
MRVL
BBIO
MRVL vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Marvell Technology, Inc. (MRVL) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MRVL | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.82 | ||
| Sortino ratioReturn per unit of downside risk | +1.92 | ||
| Omega ratioGain probability vs. loss probability | 1.55 | 1.29 | +0.27 |
| Calmar ratioReturn relative to maximum drawdown | 11.57 | 3.40 | +8.17 |
| Martin ratioReturn relative to average drawdown | 26.42 | 8.27 | +18.15 |
Loading charts...
Drawdowns
MRVL vs. BBIO - Drawdown Comparison
The maximum MRVL drawdown since its inception was -91.60%, roughly equal to the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for MRVL and BBIO.
Loading charts...
Drawdown Indicators
| MRVL | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.60% | -92.80% | +1.20% |
Max Drawdown (1Y)Largest decline over 1 year | -26.36% | -20.25% | -6.11% |
Max Drawdown (3Y)Largest decline over 3 years | -60.79% | -49.08% | -11.71% |
Max Drawdown (5Y)Largest decline over 5 years | -61.88% | -91.89% | +30.01% |
Max Drawdown (10Y)Largest decline over 10 years | -61.88% | — | — |
Current DrawdownCurrent decline from peak | -11.61% | -16.41% | +4.80% |
Average DrawdownAverage peak-to-trough decline | -46.74% | -45.77% | -0.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.52% | 8.31% | +3.21% |
Volatility
MRVL vs. BBIO - Volatility Comparison
Marvell Technology, Inc. (MRVL) has a higher volatility of 40.61% compared to BridgeBio Pharma, Inc. (BBIO) at 10.47%. This indicates that MRVL's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MRVL | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 40.61% | 10.47% | +30.14% |
Volatility (6M)Calculated over the trailing 6-month period | 55.42% | 34.18% | +21.24% |
Volatility (1Y)Calculated over the trailing 1-year period | 70.94% | 46.52% | +24.42% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 61.82% | 85.91% | -24.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 51.94% | 83.77% | -31.83% |
Dividends
MRVL vs. BBIO - Dividend Comparison
MRVL's dividend yield for the trailing twelve months is around 0.09%, while BBIO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MRVL Marvell Technology, Inc. | 0.09% | 0.28% | 0.22% | 0.40% | 0.65% | 0.21% | 0.50% | 0.90% | 1.48% | 1.12% | 1.73% | 2.72% |
Financials
MRVL vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Marvell Technology, Inc. and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MRVL vs. BBIO - Profitability Comparison
MRVL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Marvell Technology, Inc. reported a gross profit of 1.26B and revenue of 2.42B. Therefore, the gross margin over that period was 52.2%.
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
MRVL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Marvell Technology, Inc. reported an operating income of 339.40M and revenue of 2.42B, resulting in an operating margin of 14.0%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
MRVL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Marvell Technology, Inc. reported a net income of 34.50M and revenue of 2.42B, resulting in a net margin of 1.4%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
Frequently Asked Questions
MRVL and BBIO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MRVL has higher volatility (40.61%) compared to BBIO (10.47%). In terms of maximum drawdown, MRVL dropped -91.60% vs BBIO's -92.80%.
MRVL currently has the higher Sharpe Ratio (4.30 vs 1.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MRVL and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer